Revvity, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Revvity, Inc. on August 4, 2026. The filing primarily announces financial results for the second quarter ended July 5, 2026, and discloses a definitive agreement regarding the sale of a specific business segment.
Key Financial Metrics and Material Changes
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the second quarter of 2026. These details are contained in the press release furnished as Exhibit 99.1, which is not included in the provided source text.
A material change disclosed is the definitive agreement signed on July 31, 2026, to sell substantially all assets related to the Company's Immunodiagnostics business in China ("China IDX").
- Transaction Value: Up to $200 million, subject to adjustments and satisfaction of conditions.
- Expected Closing: Management believes the transaction is probable to close by the end of 2027.
- Financial Impact: Unaudited pro forma condensed consolidated financial statements reflecting this sale are included as Exhibit 99.2.
Guidance, Outlook, and Risks
Management has issued forward-looking statements regarding the anticipated sale of the China IDX assets. The filing includes a cautionary statement noting that actual results may differ materially from expectations due to various risk factors, including the Company's ability to execute divestitures.
The Company disclaims any obligation to update these forward-looking statements based on future developments.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, earnings, and cash flow figures.
- Examine Exhibit 99.2 for the unaudited pro forma financial statements detailing the impact of the China IDX divestiture.
- Verify the specific conditions and adjustment mechanisms that could alter the final sale price of the China IDX assets from the $200 million target.
- Confirm the timeline for the closing of the transaction, noting the current expectation of completion by the end of 2027.